½ÃÀ庸°í¼­
»óǰÄÚµå
1612150

¼¼°èÀÇ ¾Æ¹Ì³ë±Û¸®ÄÚ»çÀÌµå ½ÃÀå : Á¦Ç°º°, Åõ¿© °æ·Îº°, ¿ëµµº° - ¿¹Ãø(2025-2030³â)

Aminoglycosides Market by Product (Amikacin, Gentamicin, Kanamycin), Route of Administration (Injectables, Oral, Topical), Application - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 196 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

¾Æ¹Ì³ë±Û¸®ÄÚ»çÀÌµå ½ÃÀåÀº 2023³â¿¡ 19¾ï 3,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³â¿¡´Â 20¾ï 2,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, CAGR 4.76%·Î ¼ºÀåÇÒ Àü¸ÁÀ̰í, 2030³â¿¡´Â 26¾ï 7,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¾Æ¹Ì³ë±Û¸®ÄÚ»çÀ̵å´Â ÁÖ·Î ±×¶÷ À½¼º±Õ¿¡ ÀÇÇÑ ÁßÁõ ¹ÚÅ׸®¾Æ °¨¿°ÀÇ Ä¡·á¿¡ »ç¿ëµÇ´Â Ç×»ýÁ¦ÀÇ ÀÏÁ¾ÀÔ´Ï´Ù. ÀÇ·á ºÐ¾ß¿¡¼­ ±× Á߿伺Àº ÆÐÇ÷ÁõÀ̳ª °áÇÙ°ú °°Àº »ý¸íÀ» À§ÇùÇÏ´Â °¨¿°º´, ƯÈ÷ ´Ù¸¥ Ç×»ýÁ¦°¡ µèÁö ¾Ê´Â °æ¿ìÀÇ Ä¡·á¿¡ È¿°úÀûÀÎ °Í¿¡ ±âÀÎÇÕ´Ï´Ù. ¾Æ¹Ì³ë±Û¸®ÄÚ»çÀ̵åÀÇ ¿ëµµ´Â °¡ÃàÀÇ ÇコÄɾî, À½½Ä ¾ÈÀü È®º¸, Áúº´ ¹ß»ý ¿¹¹æ¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÏ´Â »ç¶÷ ¹× ¼öÀÇÇп¡ À̸¨´Ï´Ù. ÃÖÁ¾ ¿ëµµÀÇ ¹üÀ§´Â º´¿ø, Áø·á¼Ò, ¿¬±¸±â°ü, ÀǾàǰ Á¦Á¶¿¡±îÁö ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ¾Æ¹Ì³ë±Û¸®ÄÚ»çÀÌµå ½ÃÀåÀº Ç×»ýÁ¦ ³»¼º Áõ°¡ µîÀÇ ¿äÀο¡ ¿µÇâÀ» ¹Þ¾Æ È¿°úÀûÀÎ Ä¡·áÀÇ Çʿ伺ÀÌ °­Á¶µÇ¸é¼­ ½ÃÀåÀÇ ¼ö¿ä¸¦ °ßÀÎÇϰí ÀÖ½À´Ï´Ù. °Ô´Ù°¡ ½ÅÈï±¹¿¡¼­ÀÇ ¼¼±Õ °¨¿°ÁõÀÇ Áõ°¡µµ Å« ¼ºÀåÀÇ °¡´É¼ºÀ» °¡Á®¿À°í ÀÖ½À´Ï´Ù. ±×·¯³ª, ½ÃÀåÀº ¾ö°ÝÇÑ ±ÔÁ¦ÀÇ Æ²À̳ª, ½ÅÀå µ¶¼ºÀ̳ª ±Í µ¶¼º µî °úÀ× »ç¿ë¿¡ ¼ö¹ÝÇÏ´Â µ¶¼ºÀÇ °¡´É¼ºÀ̶ó°í ÇÏ´Â °úÁ¦¿¡ Á÷¸éÇϰí ÀÖ½À´Ï´Ù. ÀáÀçÀûÀÎ °¡´É¼ºÀ» »ìÆìº¸¸é ºÎÀÛ¿ëÀ» ÁÙÀ̰í À¯È¿¼ºÀ» ³ôÀÎ ¾Æ¹Ì³ë±Û¸®ÄÚ»çÀ̵å À¯µµÃ¼ °³¹ß¿¡´Â »ó´çÇÑ ±â¼ú Çõ½ÅÀÇ ¿©Áö°¡ ÀÖ½À´Ï´Ù. ³»¼º ¹ßÇöÀ» ¾ïÁ¦ÇÏ´Â º´¿ë ¿ä¹ý¿¡ ÃÊÁ¡À» ¸ÂÃá ¿¬±¸ °³¹ß¿¡ ´ëÇÑ ÅõÀÚ´Â ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇÒ °¡´É¼ºÀÌ ÀÖ½À´Ï´Ù. °Ô´Ù°¡ ½ÃÀå °ü°èÀÚ´Â ¹ÙÀÌ¿À Å×Å©³î·ÎÁö ±â¾÷°úÀÇ °øµ¿ »ç¾÷À» ¸ð»öÇØ, ¾Æ¹Ì³ë ±Û¸®ÄÚ»çÀ̵åÀÇ »ç¿ë Á¤È®µµ¸¦ ³ôÀÌ´Â ¾à¹° Àü´Þ ½Ã½ºÅÛÀ» °³¹ßÇØ¾ß ÇÕ´Ï´Ù. ÁÖ¿ä ¹ßÀü¿¡´Â, ³ôÀº °³¹ß ºñ¿ë ¹× ½ÂÀÎ ÇÁ·Î¼¼½ºÀÇ ±æÀÌ µîÀÌ ÀÖ¾î, ½Å±Ô Âü°¡¸¦ ¸·´Â ¿äÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù. ±×·¯³ª Ç×»ýÁ¦ ³»¼º ¿¬±¸¿¡ ´ëÇÑ Á¤ºÎÀÇ ¿ì´ë Á¶Ä¡¿Í ÀÚ±Ý Áö¿øÀ¸·Î °æÁ¦Àû ºÎ´ãÀÌ °æ°¨µÉ ¼ö ÀÖ½À´Ï´Ù. °³º°È­ ÀÇ·áÀÇ µ¿ÇâÀº Ç×»ý¹°ÁúÀ» °³º° ȯÀÚÀÇ ¿ä±¸¿¡ ¸Â°Ô Á¶Á¤ÇÔÀ¸·Î½á Ä¡·á ¼º°ú¸¦ ÃÖÀûÈ­ÇÒ ¼ö ÀÖ´Â °¡´É¼ºÀÌ Àֱ⠶§¹®¿¡ ½ÃÀå È®´ëÀÇ ±æÀ» º¸¿©ÁÖ°í ÀÖ½À´Ï´Ù. ½ÃÀåÀÇ °æÀïÀº ¿¬±¸ ÁÖµµÇüÀ̱⠶§¹®¿¡ Çõ½Å°ú Àü·«Àû Á¦ÈÞ¸¦ ¿ì¼±½ÃÇÏ´Â ±â¾÷¿¡°Ô´Â ±âȸ°¡ µË´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ(2023³â) 19¾ï 3,000¸¸ ´Þ·¯
¿¹Ãø³â(2024³â) 20¾ï 2,000¸¸ ´Þ·¯
¿¹Ãø³â(2030³â) 26¾ï 7,000¸¸ ´Þ·¯
CAGR(%) 4.76%

½ÃÀå ¿ªÇÐ : ºü¸£°Ô ÁøÈ­ÇÏ´Â ¾Æ¹Ì³ë±Û¸®ÄÚ»çÀÌµå ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

¾Æ¹Ì³ë±Û¸®ÄÚ»çÀÌµå ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ ÀÛ¿ë¿¡ ÀÇÇØ º¯¸ð¸¦ ÀÌ·ç°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ ÁøÈ­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÅõÀÚ°áÁ¤, Àü·«Àû ÀÇ»ç°áÁ¤, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ ȹµæÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ °æ°¨ÇÒ ¼ö ÀÖÀ» »Ó¸¸ ¾Æ´Ï¶ó, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¶Ç´Â ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ±×¶÷ À½¼º±Õ °¨¿°¿¡ ´ëÇÑ È¿°úÀûÀÎ Ä¡·á¿¡ ´ëÇÑ ¿ä±¸ Áõ°¡
    • µ¿¹°ÀÇ °¨¿°À» Ä¡·áÇϱâ À§ÇÑ µ¿¹°¿ë ÀǾàǰ ÀÌ¿ë
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ¾Æ¹Ì³ë±Û¸®ÄÚ»çÀ̵åÀÇ °³¹ß°ú Á¦Á¶¿¡ À־ÀÇ º¹À⼺
  • ½ÃÀå ±âȸ
    • ¾Æ¹Ì³ë±Û¸®ÄÚ»çÀ̵åÀÇ ¾à¹° Àü´Þ ½Ã½ºÅÛÀÇ Áøº¸
    • ¾Æ¹Ì³ë±Û¸®ÄÚ»çÀÌµå ³»¼º ¸ÞÄ¿´ÏÁòÀÇ ¿¬±¸ °³¹ß
  • ½ÃÀåÀÇ °úÁ¦
    • ¾Æ¹Ì³ë±Û¸®ÄÚ»çÀ̵忡 ÀÇÇÑ ºÎÀÛ¿ë°ú µ¶¼º

Porter's Five Forces : ¾Æ¹Ì³ë±Û¸®ÄÚ»çÀÌµå ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« µµ±¸

Porter's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲÀÇ °æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Porter's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ ޱ¸ÇÏ´Â ¸íÈ®ÇÑ ±â¼úÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÀλçÀÌÆ®¸¦ ÅëÇØ ±â¾÷Àº ÀÚ»çÀÇ °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ °úÁ¦¸¦ ÇÇÇÒ ¼ö ÀÖÀ¸¸ç, º¸´Ù °­ÀÎÇÑ ½ÃÀå¿¡¼­ÀÇ Æ÷Áö¼Å´×À» º¸ÀåÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ¾Æ¹Ì³ë±Û¸®ÄÚ»çÀÌµå ½ÃÀå¿¡¼­ ¿ÜºÎ·ÎºÎÅÍÀÇ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ¾Æ¹Ì³ë±Û¸®ÄÚ»çÀÌµå ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀÎ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¾ÕÀ¸·Î ¿¹»óµÇ´Â Àû±ØÀûÀÎ ÀÇ»ç °áÁ¤À» ÇÒ Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® : ¾Æ¹Ì³ë±Û¸®ÄÚ»çÀÌµå ½ÃÀå °æÀï ±¸µµ ÆÄ¾Ç

¾Æ¹Ì³ë±Û¸®ÄÚ»çÀÌµå ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü µî ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀï Æ÷Áö¼Å´×À» ¹àÈú ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ½ÃÀå ÁýÁß, ´ÜÆíÈ­, ÅëÇÕ µ¿ÇâÀ» ¹àÇô³»°í º¥´õµéÀº °æÀïÀÌ Ä¡¿­ÇØÁö´Â °¡¿îµ¥ ÀÚ»çÀÇ ÁöÀ§¸¦ ³ôÀÌ´Â Àü·«Àû ÀÇ»ç °áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ Áö½ÄÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º : ¾Æ¹Ì³ë±Û¸®ÄÚ»çÀÌµå ½ÃÀå¿¡¼­ °ø±Þ¾÷üÀÇ ¼º´É Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ¾Æ¹Ì³ë±Û¸®ÄÚ»çÀÌµå ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº °ø±Þ¾÷üÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±âÁØÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ¸Â´Â ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. ³× °¡Áö »çºÐ¸éÀ» ÅëÇØ °ø±Þ¾÷ü¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê ¹× ¼Ö·ç¼ÇÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× Ãßõ : ¾Æ¹Ì³ë±Û¸®ÄÚ»çÀÌµå ½ÃÀå¿¡¼­ ¼º°ø¿¡ ´ëÇÑ ±æÀ» ±×¸³´Ï´Ù.

¾Æ¹Ì³ë±Û¸®ÄÚ»çÀÌµå ½ÃÀåÀÇ Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ÀÇ ÇÁ·¹Á𽺠°­È­¸¦ ¸ñÇ¥·Î ÇÏ´Â ±â¾÷¿¡ ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ´É·Â ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í °³¼±À» À§ÇØ ³ë·ÂÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀ» ÅëÇØ °æÀï ±¸µµ¿¡¼­ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ üÁ¦¸¦ ±¸ÃàÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀåÀÇ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·ÂÀ» Æò°¡ÇÕ´Ï´Ù.

2. ½ÃÀå °³Ã´µµ : ½ÅÈï ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡ÇÏ¸ç ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù¾çÈ­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä Áøº¸, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú Áøº¸ µîÀ» °ËÁõÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÃÖ÷´Ü ±â¼ú, ¿¬±¸°³¹ß Ȱµ¿, Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚ°¡ ÃæºÐÇÑ Á¤º¸¸¦ ¾ò°í ÀÇ»ç°áÁ¤À» ÇÒ ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡ ´ë´äÇϰí ÀÖ½À´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð ¹× ÇâÈÄ ¼ºÀå ¿¹ÃøÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹® ¹× Áö¿ªÀº ¾îµðÀԴϱî?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ ¹× ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À² ¹× °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • ±×¶÷ À½¼º ¼¼±Õ °¨¿°ÁõÀÇ È¿°úÀûÀÎ Ä¡·á¹ýÀÇ Çʿ伺 Áõ°¡
      • µ¿¹°ÀÇ °¨¿°Áõ Ä¡·á¿¡¼­ ¼öÀÇÇÐÀÇ ÀÌ¿ë
    • ¾ïÁ¦¿äÀÎ
      • ¾Æ¹Ì³ë±Û¸®ÄÚ»çÀ̵åÀÇ °³¹ß°ú Á¦Á¶¿¡ À־ÀÇ º¹À⼺
    • ±âȸ
      • ¾Æ¹Ì³ë±Û¸®ÄÚ»çÀ̵åÀÇ ¾à¹° Àü´Þ ½Ã½ºÅÛÀÇ Áøº¸
      • ¾Æ¹Ì³ë±Û¸®ÄÚ»çÀÌµå ³»¼º ±â±¸ÀÇ ¿¬±¸ °³¹ß
    • °úÁ¦
      • ¾Æ¹Ì³ë±Û¸®ÄÚ»çÀ̵忡 ÀÇÇÑ ºÎÀÛ¿ë°ú µ¶¼º
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
    • Á¦Ç°º°: Ç÷¾×, º¹ºÎ, Æó, ÇǺÎ, ¿¬ºÎ Á¶Á÷ÀÇ °¨¿°ÁõÀÇ Ä¡·á¿¡ ³Î¸® ÀÌ¿ëµÇ°í ÀÖ´Â °ÕŸ¸¶À̽Å
    • ¿ëµµº° : È£Èí±â Áúȯ Àü¹Ý¿¡ °ÉÄ£ ¾Æ¹Ì³ë±Û¸®ÄÚ»çÀ̵åÀÇ È°¿ë
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡Àû
    • °æÁ¦
    • »ç±³
    • ±â¼úÀû
    • ¹ý·ü»ó
    • ȯ°æ

Á¦6Àå ¾Æ¹Ì³ë±Û¸®ÄÚ»çÀÌµå ½ÃÀå : Á¦Ç°º°

  • ¾Æ¹ÌÄ«½Å
  • °ÕŸ¸¶À̽Å
  • Ä«³ª¸¶À̽Å
  • ³×¿À¸¶À̽Å
  • ÆÄ·Î¸ð¸¶À̽Å
  • ½ºÆ®·¾Å丶À̽Å
  • Åäºê¶ó¸¶À̽Å

Á¦7Àå ¾Æ¹Ì³ë±Û¸®ÄÚ»çÀÌµå ½ÃÀå : Åõ¿© °æ·Îº°

  • ÁÖ»çÁ¦
  • ¿À¶ö
  • È­Á¦

Á¦8Àå ¾Æ¹Ì³ë±Û¸®ÄÚ»çÀÌµå ½ÃÀå : ¿ëµµº°

  • È£Èí±â Áúȯ
  • ÇǺΠ°¨¿°Áõ
  • ¿ä·Î °¨¿° ¹× °ñ¹Ý Áúȯ
  • ¼öÀÇÇÐ

Á¦9Àå ¾Æ¸Þ¸®Ä«ÀÇ ¾Æ¹Ì³ë±Û¸®ÄÚ»çÀÌµå ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦10Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¾Æ¹Ì³ë±Û¸®ÄÚ»çÀÌµå ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦11Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ¾Æ¹Ì³ë±Û¸®ÄÚ»çÀÌµå ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦12Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®(2023³â)
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º(2023³â)
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
    • Cipla Limited, Àεµ¿¡¼­ ÁøÇ༺ ¿ä·Î °¨¿°Áõ Ä¡·áÁ¦ ÇÁ¶óÁ¶¸¶À̽ÅÀ» ¹ßÇ¥
    • ¾ÈÀü¼º Çâ»óÀ» À§ÇÑ ¾Æ¹Ì³ë±Û¸®ÄÚ»çÀ̵å°è Ç×»ýÁ¦ÀÇ Çõ½Å : ³­Ã» À§ÇèÀÇ °æ°¨
    • BDR Pharmaceuticals, Èñ¼Ò ¼Ò¾Æ ¹× ¼ºÀÎ ¹éÇ÷º´ Ä¡·á¿¡ À־ÀÇ »õ·Î¿î Á¢±Ù¹ý, ´Ï·ÎƼ´Õ ¹ß¸Å
  • Àü·« ºÐ¼® ¹× Á¦¾È

±â¾÷ ¸ñ·Ï

  • AbbVie Inc.
  • AstraZeneca plc
  • Bristol Myers Squibb Company
  • Cipla Limited
  • GlaxoSmithKline plc
  • Hangzhou Uniwise International Co., Ltd.
  • HuvePharma
  • Insmed Incorporated
  • Jiangxi Bolai Pharmacy Co., Ltd.
  • Kremoint Pharma Pvt. Ltd
  • Medico Remedies Pvt. Ltd.
  • Medson Pharmaceuticals
  • Novartis AG
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd
  • Vega Pharma Ltd.
  • Zoetis Inc.
AJY 24.12.24

The Aminoglycosides Market was valued at USD 1.93 billion in 2023, expected to reach USD 2.02 billion in 2024, and is projected to grow at a CAGR of 4.76%, to USD 2.67 billion by 2030.

Aminoglycosides are a class of antibiotics used primarily to treat severe bacterial infections, particularly those caused by gram-negative bacteria. Their importance in the medical field stems from their effectiveness in treating life-threatening infections like sepsis and tuberculosis, especially when other antibiotics fail. The application of aminoglycosides spans human and veterinary medicine, where they play a crucial role in livestock healthcare, ensuring food safety, and the prevention of disease outbreaks. The end-use scope extends to hospitals, clinics, research institutions, and pharmaceutical manufacturing. The market for aminoglycosides is influenced by factors such as rising antibiotic resistance, which underscores the necessity for effective treatments and drives market demand. Additionally, the growing incidences of bacterial infections in emerging economies provide significant growth potential. However, the market faces challenges from stringent regulatory frameworks and the potential for toxicity associated with overuse, such as nephrotoxicity and ototoxicity. Exploring potential opportunities, there is considerable room for innovation in developing aminoglycoside derivatives with reduced side effects and enhanced efficacy. Investment in research focused on combination therapies that reduce resistance development can further propel market growth. Moreover, market players should explore joint ventures with biotechnological firms to advance drug delivery systems that enhance the precision of aminoglycoside usage. Key limitations include the high cost of development and the lengthy approval process, which can deter new entrants. However, government incentives and funding for antibiotic resistance research may alleviate some financial burdens. Trends toward personalized medicine present an avenue for market expansion, as tailoring antibiotics to individual patient needs could optimize therapeutic outcomes. The nature of the aminoglycosides market is competitive and research-driven, presenting opportunities for enterprises that prioritize innovation and strategic collaborations.

KEY MARKET STATISTICS
Base Year [2023] USD 1.93 billion
Estimated Year [2024] USD 2.02 billion
Forecast Year [2030] USD 2.67 billion
CAGR (%) 4.76%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Aminoglycosides Market

The Aminoglycosides Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rise in need for effective treatments for gram-negative bacterial infections
    • Utilization veterinary medicine to treat infections in animals
  • Market Restraints
    • Complexities in development and manufacturing of aminoglycosides
  • Market Opportunities
    • Advancements in drug delivery systems for aminoglycosides
    • Research and development into aminoglycoside resistance mechanisms
  • Market Challenges
    • Side effects and toxicity caused due to aminoglycosides

Porter's Five Forces: A Strategic Tool for Navigating the Aminoglycosides Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Aminoglycosides Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Aminoglycosides Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Aminoglycosides Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Aminoglycosides Market

A detailed market share analysis in the Aminoglycosides Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Aminoglycosides Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Aminoglycosides Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Aminoglycosides Market

A strategic analysis of the Aminoglycosides Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Aminoglycosides Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AstraZeneca plc, Bristol Myers Squibb Company, Cipla Limited, GlaxoSmithKline plc, Hangzhou Uniwise International Co., Ltd., HuvePharma, Insmed Incorporated, Jiangxi Bolai Pharmacy Co., Ltd., Kremoint Pharma Pvt. Ltd, Medico Remedies Pvt. Ltd., Medson Pharmaceuticals, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd, Vega Pharma Ltd., and Zoetis Inc..

Market Segmentation & Coverage

This research report categorizes the Aminoglycosides Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Amikacin, Gentamicin, Kanamycin, Neomycin, Paromomycin, Streptomycin, and Tobramycin.
  • Based on Route of Administration, market is studied across Injectables, Oral, and Topical.
  • Based on Application, market is studied across Respiratory Diseases, Skin Infection, UTI & Pelvic Diseases, and Veterinary Medicine.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rise in need for effective treatments for gram-negative bacterial infections
      • 5.1.1.2. Utilization veterinary medicine to treat infections in animals
    • 5.1.2. Restraints
      • 5.1.2.1. Complexities in development and manufacturing of aminoglycosides
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in drug delivery systems for aminoglycosides
      • 5.1.3.2. Research and development into aminoglycoside resistance mechanisms
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects and toxicity caused due to aminoglycosides
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Wide utilization of gentamicin to treat infections in the blood, abdomen, lungs, skin, and soft tissues
    • 5.2.2. Application: Employment of aminoglycosides across respiratory diseases
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Aminoglycosides Market, by Product

  • 6.1. Introduction
  • 6.2. Amikacin
  • 6.3. Gentamicin
  • 6.4. Kanamycin
  • 6.5. Neomycin
  • 6.6. Paromomycin
  • 6.7. Streptomycin
  • 6.8. Tobramycin

7. Aminoglycosides Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Injectables
  • 7.3. Oral
  • 7.4. Topical

8. Aminoglycosides Market, by Application

  • 8.1. Introduction
  • 8.2. Respiratory Diseases
  • 8.3. Skin Infection
  • 8.4. UTI & Pelvic Diseases
  • 8.5. Veterinary Medicine

9. Americas Aminoglycosides Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Aminoglycosides Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Aminoglycosides Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Cipla Limited Unveils Plazomicin for Advanced Urinary Tract Infection Management in India
    • 12.3.2. Innovating Aminoglycoside Antibiotics for Enhanced Safety: Mitigating Hearing Loss Risks
    • 12.3.3. BDR Pharmaceuticals Launches Nilotinib: A Novel Approach in the Treatment of Rare Childhood and Adult Leukemia
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. AstraZeneca plc
  • 3. Bristol Myers Squibb Company
  • 4. Cipla Limited
  • 5. GlaxoSmithKline plc
  • 6. Hangzhou Uniwise International Co., Ltd.
  • 7. HuvePharma
  • 8. Insmed Incorporated
  • 9. Jiangxi Bolai Pharmacy Co., Ltd.
  • 10. Kremoint Pharma Pvt. Ltd
  • 11. Medico Remedies Pvt. Ltd.
  • 12. Medson Pharmaceuticals
  • 13. Novartis AG
  • 14. Pfizer Inc.
  • 15. Teva Pharmaceutical Industries Ltd
  • 16. Vega Pharma Ltd.
  • 17. Zoetis Inc.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦